Drug Profile

XL 844

Alternative Names: EXEL-9844; XL844

Latest Information Update: 17 Dec 2008

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Exelixis
Class Antineoplastics
Mechanism of Action Checkpoint kinase 1 inhibitors; Checkpoint kinase 2 inhibitors; Checkpoint kinase inhibitors; Vascular endothelial growth factor receptor-2 antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Cancer; Chronic lymphocytic leukaemia

Most Recent Events

17 Dec 2008 Discontinued - Phase-I for Cancer in USA (PO)
17 Dec 2008 Discontinued - Phase-I for Chronic lymphocytic leukaemia in USA (PO)
23 Oct 2008 GlaxoSmithKline decides not to license XL 844

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com